MedTrace Logo

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

NCT04627012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-03-06

No results posted yet for this study

Summary

For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC. This study will create a database that will provide clinical parameters and outcomes of patients undergoing Lenvatinib and anti-PD1 antibody as part of their standard of care in hopes of answering key clinical questions.

Conditions

Interventions

DRUG

Lenvatinib

12 mg (or 8 mg) once daily (QD) oral dosing.

DRUG

Opdivo

3mg/mg intravenously every 3 weeks

DRUG

Camrelizumab

200mg intravenously every 3 weeks

DRUG

Keytruda

200mg intravenously every 3 weeks

DRUG

Toripalimab

240mg intravenously every 3 weeks

DRUG

Sintilimab

200mg intravenously every 3 weeks

DRUG

Tislelizumab

200mg intravenously every 3 weeks

Sponsors & Collaborators

  • Second Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-12-30
Completion
2023-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04627012 on ClinicalTrials.gov